2004
DOI: 10.1097/01.ccm.0000127775.70867.0c
|View full text |Cite
|
Sign up to set email alerts
|

Treatment with a novel poly(ADP-ribose) glycohydrolase inhibitor reduces development of septic shock-like syndrome induced by zymosan in mice

Abstract: This study supports early studies that show efficacy from blocking the poly(ADP-ribose) pathway in septic shock-like syndrome model. It provides evidence that GPI 18214, a PARG inhibitor, attenuates the degree of zymosan-induced nonseptic shock in mice, suggesting that PARG may be an alternative therapeutic target for shock treatment.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
33
0

Year Published

2005
2005
2014
2014

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 53 publications
(33 citation statements)
references
References 29 publications
0
33
0
Order By: Relevance
“…Some of them have already been shown to associate with inflammatory pathologies: such as PARP-2 (reviewed in [35]), PARP-3 [36], tankyrases [79], or PARP-14 [30,31]. Moreover, poly(ADP-ribose) glycohydrolase has been implicated in the regulation of immune functions [80,81] underlining the central role of poly(ADP-ribosyl)ation in inflammation. A key question is whether the powerful anti-inflammatory effects of PARP inhibitors as observed in animal models can be translated to human diseases and to determine the risk benefit ratio of acute and chronic administration of PARP inhibitors in non-cancer patients.…”
Section: Resultsmentioning
confidence: 99%
“…Some of them have already been shown to associate with inflammatory pathologies: such as PARP-2 (reviewed in [35]), PARP-3 [36], tankyrases [79], or PARP-14 [30,31]. Moreover, poly(ADP-ribose) glycohydrolase has been implicated in the regulation of immune functions [80,81] underlining the central role of poly(ADP-ribosyl)ation in inflammation. A key question is whether the powerful anti-inflammatory effects of PARP inhibitors as observed in animal models can be translated to human diseases and to determine the risk benefit ratio of acute and chronic administration of PARP inhibitors in non-cancer patients.…”
Section: Resultsmentioning
confidence: 99%
“…Based on the known PARG inhibitory effect of gallotannin and the antiinflammatory effect of a recently developed nontannin PARG inhibitor (Genovese et al, 2004), we have also investigated the effect of GT on poly(ADP-ribose) metabolism as a possible mechanism underlying the anti-inflammatory effect of GT. Treatment of the cells with the cytokines for various time Fig.…”
Section: Gallotannin Inhibits Cytokine and Chemokine Expression 899mentioning
confidence: 99%
“…In vivo validation on the interaction of the CD5 ectodomain with fungal constituents was obtained from the mouse model of septic shock-like syndrome induced by zymosan (26). In this model, administration of a single dose of zymosan (500 mg/kg, i.p.)…”
Section: The Soluble Cd5 Ectodomain Protects From Zymosan-induced Septicmentioning
confidence: 99%